From Financialpost · · 1m 20s
Junshi Biosciences Completes First Patient Dosing for HCC Trial
Junshi Biosciences completes first patient dosing in phase 3 trial for advanced liver cancer treatment.
In brief
Junshi Biosciences completes first patient dosing in phase 3 trial for advanced liver cancer treatment. Junshi Biosciences completed first patient dosing in phase 3 trial for advanced hepatocellular carcinoma treatment using JS207 and JS007 combination therapy. Originally reported by Financialpost.
Junshi Biosciences Announces Trial Completion
Shanghai Junshi Biosciences Co., Ltd announced completion of first patient dosing in a phase 3 clinical trial for advanced hepatocellular carcinoma treatment.
Hepatocellular Carcinoma Burden in China
China accounts for approximately 354,100 new liver cancer cases and 303,800 deaths in 2024, making it the second leading cause of cancer-related death after lung cancer.
Current Treatment Limitations
Current first-line systemic therapies for intermediate and advanced liver cancer have median overall survival less than 2 years.
Phase 2 Results Presented at ESMO 2026
JS207 in combination with JS007 showed 44.1% objective response rate and 85.3% disease control rate in phase 2 study.
Phase 3 Study Design
JS207-017-III-HCC study plans to enroll 560 subjects comparing JS207+JS007 to toripalimab+bevacizumab for first-line advanced hepatocellular carcinoma.
JS207 Mechanism of Action
JS207 simultaneously binds to PD-1 and VEGFA to block tumor growth and improve immune response.
Next Steps for Treatment
The phase 3 trial will assess progression-free survival and overall survival for advanced hepatocellular carcinoma patients.
The takeaway
Junshi Biosciences completed first patient dosing in phase 3 trial for advanced hepatocellular carcinoma treatment using JS207 and JS007 combination therapy.
